Biomatter

Based in Vilnius, Lithuania, Biomatter is a synthetic biology company that utilizes generative artificial intelligence to design novel proteins and enzymes from scratch. The organization operates a proprietary platform called Intelligent Architecture, which allows protein engineers to create custom enzymes for chemical biomanufacturing, agriculture, and therapeutics while reducing development cycles from years to weeks. The venture-backed enterprise has raised €7 million in total capital, including a €6.5 million seed funding round completed in May 2024. Biomatter generates revenue through business-to-business partnerships and co-development agreements to design custom proteins for enterprise clients. The firm maintains commercial relationships with notable corporate customers such as Thermo Fisher Scientific, BASF, and Kirin, while receiving financial backing from lead investors Inventure and UVC Partners. The company was founded in 2018 by Laurynas Karpus, Vykintas Jauniskis, Rolandas Meskys, and Donatas Repecka.